Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie Inc    ABBV

ABBVIE INC (ABBV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/16/2017 03/17/2017 03/20/2017 03/21/2017 03/22/2017 Date
65.9(c) 65.69(c) 65.8(c) 65.35(c) 65.52(c) Last
5 162 786 11 288 046 4 252 114 5 187 438 5 662 572 Volume
-0.98% -0.32% +0.17% -0.68% +0.26% Change
More quotes
Financials ($)
Sales 2017 27 734 M
EBIT 2017 11 910 M
Net income 2017 7 904 M
Debt 2017 27 035 M
Yield 2017 3,93%
Sales 2018 30 330 M
EBIT 2018 13 775 M
Net income 2018 9 355 M
Debt 2018 22 251 M
Yield 2018 4,33%
P/E ratio 2017 13,81
P/E ratio 2018 11,76
EV / Sales2017 4,74x
EV / Sales2018 4,18x
Capitalization 104 411 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
04/11Ex-dividend day
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
12:52p ABBVIE : Julianne Hough Empowers Women to "Get in the Know" About Endometriosis
03/21 ABBVIE : holds PD communicate initiative
03/20 ABBVIE INC : Update in Lawsuit for Investors in NYSE: ABBV Shares Against AbbVie..
03/17 Global Divalproex Sodium Market- AbbVie , Aurobindo Pharma, Mylan , Dr Reddys..
03/17 ABBVIE : Japans MHLW grants priority review for AbbVies chronic HCV treatment
03/14 AbbVie Inc Shares Sold by Jupiter Asset Management Ltd.
03/11 INSIDER TRADING ACTIVITY ABBVIE INC : ABBV) – VP Sold 5,132 shares of Sto..
03/11 INSIDER TRADING ACTIVITY ABBVIE INC : ABBV) – Chairman Sold 72,016 shares..
03/11 INSIDER TRADING ACTIVITY ABBVIE INC : ABBV) – Insider Sold 40,000 shares ..
03/11 INSIDER TRADING ACTIVITY ABBVIE INC : ABBV) – SVP Sold 22,451 shares of S..
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE INC 
2015A likely recovery
More Strategies
Latest Tweets
03/22RECAP 3/22 +Pos Comments: $CBD $VSTO $ABBV $IIIN $CERN -Neg Comments: $HTZ $T..
3
03/22AbbVie upgraded by Societe Generale to neutral.  
03/22Galapagos initiates early-stage study on CF candidate GLPG3067, earns $7.5M m..
1
03/22AbbVie's hold rating reiterated at BMO Capital Markets. $63.00 PT.  
03/21AbbVie: Good For Value, Good For Growth $AMGN $NVS $ABBV  
More tweets
Qtime:190
News from SeekingAlpha
03/22 Galapagos initiates early-stage study on CF candidate GLPG3067, earns $7.5M m..
03/21 ABBVIE : Good For Value, Good For Growth
03/21 UCB Needs Clinical Success To Drive Upside
03/21 THREATS AND OPPORTUNITIES IN PSORIAS : What's Next For Novartis?
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 71,0 $
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC4.63%104 411
MERCK KGAA2.42%14 174
KYOWA HAKKO KIRIN CO L..3.96%8 712
JAZZ PHARMACEUTICALS P..30.55%8 504
CONVATEC GROUP PLC13.00%6 305
MALLINCKRODT PLC-14.61%4 454
More Results